Hot Consumer Service Stocks To Watch For 2014

Over the past two months, I have reported on weakening unit revenue trends within the airline industry. While the industry bottomed out in April, results in May were still fairly unsatisfactory at most carriers. Airlines are benefiting somewhat from lower fuel prices and planes are more packed than ever before, but pricing power has been extremely weak. As a result, most carriers suffered a second straight monthly decline in unit revenue.

Airline

Unit Revenue Change

Capacity Change

AMR (NASDAQOTH: AAMRQ  )

Down 1.8%

Up 0.3%

Delta Air Lines (NYSE: DAL  )

Up 0.5%

Up 0.7%

Hot Wireless Telecom Stocks To Buy Right Now: Somaxon Pharmaceuticals Inc.(SOMX)

Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the in-licensing, development, and commercialization of proprietary branded products and late-stage product candidates for the treatment medical conditions in the central nervous system therapeutic area. Its product includes Silenor for the treatment of insomnia characterized by difficulty with sleep maintenance. The company sells its products to wholesale distributors in the United States. Somaxon Pharmaceuticals, Inc. was founded in 2003 and is headquartered in San Diego, California.

Advisors' Opinion:

• [By CRWE]

  Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX), a specialty pharmaceutical company, will release its financial results for the third quarter ended September 30, 2012 on Wednesday, October 31, 2012 after the close of the U.S. financial markets.

Hot Consumer Service Stocks To Watch For 2014: Bulova Technologies Group Inc (BTGI)

Bulova Technologies Group, Inc. (BLVT), incorporated in 1979, operates as a Government contractor in the United States. BLVT�� operating facilities are located in Mayo, Florida. As of September 30, 2011, the Company is focused on Department of Defense contracting. As of September 30, 2011, BLVT operated corporate and administrative offices in two leased facilities, one in Clearwater, Florida, approximating 2,400 square feet, and the other in Brandon, Florida, approximating 5,000 square feet. The Company�� Government contracting business is located on 261 acres owned by the Company in Mayo, Florida, where it operates a load, assembly, and pack facility specializing in fuzes, safe and arming devices and explosive simulators. There are more than 38 buildings on the property consisting of warehouses, storage, and manufacturing facilities. In March 31, 2011, the Company disposed of its subsidiary BT Manufacturing Company LLC. In October 2012, the Company sold Bulova Technologies Ordnance Systems LLC.

Bulova Technologies Ordnance Systems LLC is a load, assembly, and pack facility specializing in fuzes, safe and arming devices and explosive simulators. Bulova Technologies Ordnance Systems LLC produces a range of pyrotechnic devices, ammunition and other energetic materials for the United States Government and other allied Governments worldwide. Bulova Technologies (Europe) LLC is developing a mortar exchange program to facilitate the needs of NATO member countries.

Advisors' Opinion:

• [By Peter Graham]

  A quick look at Hybrid Coating Technologies��financials reveals revenues of $48k (most recent reported quarter), $5k, $3k and $53k for the past four reported quarters along with net losses of $821k (most recent reported quarter), $1,571k, $774k and $510. At the end of September, Hybrid Coating Technologies had no cash to cover $4,037k in current liabilities and $1,279k in long term debt. So while the global industrial and specialty coatings market might be worth $35 billion, Hybrid Coating Technologies has yet to grab enough of it.

  Bulova Technologies Group, Inc (OTCMKTS: BTGI) Recently Did a Reverse Split

  Small cap Bulova Technologies Group has an extensive history of large scale Defense Contracts for munitions, weapons systems and combat systems. On Friday, Bulova Technologies Group fell 13.04% to $0.0300 for a market cap of $663,789 plus BTGI is up 29,900% over the past year and down 66.7% over the past five years according to Google Finance.

Hot Consumer Service Stocks To Watch For 2014: Inovio Pharmaceuticals Inc (INO)

Inovio Pharmaceuticals, Inc., incorporated on June 29, 1983, is engaged in the development of a new generation of vaccines, called synthetic vaccines, focused on cancers and infectious diseases. The Company's SynCon technology enables the design of universal vaccines capable of providing cross-protection against existing or changing strains of pathogens, such as influenza and human immunodeficiency virus (HIV). The Company's electroporation delivery technology uses brief, controlled electrical pulses to increase cellular uptake of the vaccine. Its clinical programs include cervical dysplasia (therapeutic), avian influenza (preventive), prostate cancer (therapeutic), leukemia (therapeutic), hepatitis C virus (HCV) and HIV vaccines. It is advancing preclinical research and clinical development for a universal seasonal/pandemic influenza vaccine, as well as preclinical work for other products, including malaria and prostate cancer vaccines. Its partners and collaborators include University of Pennsylvania, Drexel University, National Microbiology Laboratory of the Public Health Agency of Canada, Program for Appropriate Technology in Health/Malaria Vaccine Initiative (PATH/MVI), National Institute of Allergy and Infectious Diseases (NIAID), Merck, ChronTech, University of Southampton, United States Military HIV Research Program (USMHRP), the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and HIV Vaccines Trial Network (HVTN). As of December 31, 2011 it owned 16.1% interest in VGX Int��.

Inovio�� Solution

The Company�� synthetic vaccine platform consists of its SynCon vaccine design process and electroporation delivery technology. It has developed a preclinical and clinical stage pipeline of vaccines. The Company�� synthetic vaccines are designed to prevent a disease (prophylactic vaccines) or treat an existing disease (therapeutic vaccines). Its synthetic vaccine consists of a deoxyribonucleic acid (DNA) plasmid encoding a selected antigen! (s), which is introduced into cells of humans or animals with the purpose of evoking an immune response to the encoded antigen. The Company�� synthetic vaccines are designed to generate specific antibody and/or T-cell responses.

The Company�� SynCon technology provides processes that employ bioinformatics, which combine extensive genetic data and sophisticated algorithms. Its design process uses the genetic make-up of a common antigen(s) from multiple strains of a virus within a viral sub-type or taxonomic group (family) of pathogens, such as HIV, hepatitis C virus (HCV), human papillomavirus (HPV), influenza and other diseases to synthetically create a new antigen for the desired pathogen target that does not exist in nature. Its synthetic vaccine candidates are being delivered into cells of the body using its electroporation (EP) DNA delivery technology.

Cancer Synthetic Vaccines

The Company has two broad types of cancer vaccines: preventive (or prophylactic) vaccines, which are intended to prevent cancer from developing in healthy people, and treatment (or therapeutic) vaccines, which are intended to treat an existing cancer by strengthening the body�� natural defenses against the cancer. Two types of cancer preventive vaccines are available in the United States. The United States Food and Drug Administration (the FDA) has approved two vaccines, Gardasil and Cervarix that protect against infection by the two types of HPV-types 16 and 18-that cause approximately 70% of all cases of cervical cancer worldwide. In addition, Gardasil protects against infection by two additional HPV types, 6 and 11, which are responsible for about 90% of all cases of genital warts in males and females but do not cause cervical cancer.

Cervarix manufactured by GlaxoSmithKline, is composed of virus-like particles (VLPs) made with proteins from HPV types 16 and 18. Cervarix is approved for use in females��ages 10 to 25 for the prevention of cervical cancer caused by! HPV type! s 16 and 18. Gardasil manufactured by Merck, is approved for use in females for the prevention of cervical cancer, and some vulvar and vaginal cancers, caused by HPV types 16 and 18 and for use in males and females for the prevention of genital warts caused by HPV types 6 and 11. The vaccine is approved for these uses in females and males ages 9 to 26. The FDA has also approved a cancer preventive vaccine that protects against hepatitis B virus (HBV) infection.

Inovio�� VGX-3100 is designed to raise immune responses against the E6 and E7 genes of HPV types 16 and 18 that are present in both pre-cancerous and cancerous cells transformed by these HPV types. E6 and E7 are oncogenes that play an integral role in transforming HPV-infected cells into cancerous cells. In March 2011, it initiated a randomized, double-blind Phase II study of VGX-3100 delivered using the CELLECTRA intramuscular electroporation device in women with HPV Type 16 or 18 and diagnosed with, but not yet treated for, cervical intraepithelial neoplasia (CIN) 2/3. The study is designed to enroll 148 subjects. In January 2011, it announced the publication of a scientific paper in the journal Human Vaccines detailing potent immune responses in a preclinical study of its SynCon vaccine for prostate cancer targeting two antigens, prostate specific antigen (PSA) and prostate specific membrane antigen (PSMA).

In January 2011, the Company announced the regulatory approval of a Phase II clinical trial (WIN Trial) to treat leukemia utilizing its new ELGEN 1000 automated vaccine delivery device. The single dose level, Phase II study, called WT1 immunity via DNA fusion gene vaccination in haematological malignancies by intramuscular injection followed by intramuscular electroporation. Cancer Vaccines encodes for hTERT, an antigen related to non-small cell lung, breast and prostate cancers. The vaccine is delivered using its electroporation delivery technology.

Infectious Disease Synthetic Vaccines

In Marc! h 2011, the Company announced the initiation of a follow-on open label, single dose Phase II clinical study in collaboration with ChronTech of the ChronVac-C HCV DNA vaccine delivered using its electroporation technology in treatment naive HCV infected individuals. Its HIV vaccines consist of candidates for HIV prevention, as well as therapy or treatment. PENNVAX-B is designed to target HIV clade B (most commonly found in the United States, North America, Australia and the European Union (EU). PENNVAX-G is designed to target HIV clades A, C and D, which are more commonly found in Asia, Africa, Russia and South America. This Phase I clinical study of PENNVAX-B (HVTN-080) vaccinated 48 healthy, HIV-negative volunteers to assess safety and levels of immune responses generated by Inovio�� PENNVAX-B vaccine delivered with its CELLECTRA electroporation device. PENNVAX-B is a SynCon vaccine that targets HIV gag, pol, and env proteins.

The Company�� VGX-3400X targets H5N1. The vaccine consists of three distinct DNA plasmids coded for a consensus hemagglutinin (HA) antigen derived from different H5N1 virus strains; a consensus neuraminidase (NA) antigen derived from different N1 sequences; and a consensus nucleoprotein (NP) fused to a small portion of the m2 protein (m2E) based on a broader cross-section of influenza viruses in addition to H5N1 and H1N1. Conventional vaccines are strain-specific and have limited ability to protect against genetic shifts in the influenza strains they target. They are therefore modified annually in anticipation of the next flu season�� new strain(s). It is focused on developing DNA-based influenza vaccines able to provide broad protection against known as well as newly emerging, unknown seasonal and pandemic influenza strains.

Animal Health/Veterinary

VGX Animal Health, Inc. (VGX AH), a majority-owned subsidiary, has licensed LifeTide, a plasmid-based growth hormone releasing hormone (GHRH) technology for swine. LifeTide is one of onl! y four DN! A-based treatments approved for use in animals and is the only DNA-based agent delivered using electroporation that has been granted marketing approval (Australia). VGX AH is also developing a GHRH-based treatment for cancer and anemia in dogs and cats. It is developing a synthetic vaccine for foot-and-mouth disease (FMD) administered by its vaccine delivery technology. The FMD virus is one of the most infectious diseases affecting farm animals, including cattle, swine, sheep and goats, and is a serious threat to global food safety.

The Company competes with Crucell N.V, Sanofi-Aventis, Novartis, Inc., GlaxoSmithKline plc, Merck, Pfizer, AstraZeneca, Inc., Novartis, Inc., MedImmune and CSL.

Advisors' Opinion:

• [By Jake L'Ecuyer]

  Equities Trading DOWN
  Shares of Inovio Pharmaceuticals (NYSE: INO) were down on Friday's session, falling 13.28 percent to $2.488 despite seemingly little news on the company.

• [By MONEYMORNING]

  Inovio Zooms: We recommended biotech Inovio Inc. (NYSE: INO) at 71 cents a share back on Feb. 1, 2013, and have re-recommended it a number of times since. With their 15.2% gain yesterday, the shares are now at $3.71, up 414% from where we first told you about them - and we believe there's more to come. In fact, we'll be bringing you an interesting update on this company very soon. Inovio is one of 24 recommendations that have doubled or better since we launched Private Briefing back in August 2011.

• [By George Budwell]

  Inovio Pharmaceuticals (NYSEMKT: INO  ) develops DNA-based vaccines and delivers them using a proprietary electroporation technique. Shares of Inovio have been a roller coaster all year long, and have certainly been the playground of day traders. Last week, Inovio shares lost more than 10% of their value on heavy volume, suggesting the stock may continue to experience downward pressure. This rapid move downward is surprising because the company recently signed a licensing deal with Roche (NASDAQOTH: RHHBY  ) to commercialize Inovio's multi-antigen DNA immunotherapies for prostate cancer and hepatitis B. As part of the deal, Inovio received $10 million upfront, and milestone payments could go as high as $412 million.

• [By Jake L'Ecuyer]

  Inovio Pharmaceuticals (NYSE: INO) was also up, gaining 10.53 percent to $3.57 after the company received the ��est Theraputic Vaccine��award at the World Vaccine Congress after the close Wednesday.

Hot Consumer Service Stocks To Watch For 2014: Mattson Technology Inc.(MTSN)

Mattson Technology, Inc. engages in the design, manufacture, marketing, and support of semiconductor wafer processing equipment used in the fabrication of integrated circuits for the semiconductor industry worldwide. Its dry strip products include the SUPREMA strip system that incorporates its inductively coupled plasma (ICP) technology photoresist process module, and vacuum-based productivity platform for processing of sub 30 nm devices. The company?s rapid thermal processing products include the Helios and Helios XP systems for conventional annealing applications, and the Millios system for millisecond anneal applications. Its etch products comprise the paradigmE and Alpine that feature a proprietary Faraday-shielded ICP with etch bias control to provide process on-wafer performance. The company sells its products directly, as well as through distribution agreements to foundries, and memory and logic device manufacturers. Mattson Technology, Inc. was founded in 1988 and is headquartered in Fremont, California.

Advisors' Opinion:

• [By Roberto Pedone]

  Mattson Technology (MTSN) designs, manufactures and markets semiconductor wafer processing equipment used in the fabrication of integrated circuits. This stock closed up 5.1% to $2.25 in Tuesday's trading session.

  Tuesday's Range: $2.15-$2.30
  
  52-Week Range: $0.70-$2.55
  
  Tuesday's Volume: 593,000
  
  Three-Month Average Volume: 825,998

  From a technical perspective, MTSN bounced higher here back above its 50-day moving average at $2.23 with lighter-than-average volume. It looks like MTSN has now put in a double bottom chart pattern, since the stock has found some buying interest over the last month at $2.05 to $2.07. If that bottom can hold, then shares of MTSN will not set up to trigger a major breakout trade. That trade will hit if MTSN manages to take out some near-term overhead resistance levels at $2.40 to $2.52 and then once it clears its 52-week high at $2.55 with high volume.

  Traders should now look for long-biased trades in MTSN as long as it's trending above $2.07 to $2.05 and then once it sustains a move or close above those breakout levels with volume that hits near or above 825,998 shares. If that breakout hits soon, then MTSN will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that breakout are its next major overhead resistance levels at $3.17 to its three-year high at $3.30.